THEMISMED

Themis Medicare Share Price

₹289.55 +3.35 (1.17%)

21 Nov, 2024 14:04

SIP TrendupStart SIP in THEMISMED

Start SIP

Performance

  • Low
  • ₹284
  • High
  • ₹294
  • 52 Week Low
  • ₹153
  • 52 Week High
  • ₹317
  • Open Price₹287
  • Previous Close₹286
  • Volume453,218

Investment Returns

  • Over 1 Month + 8.71%
  • Over 3 Month + 9.95%
  • Over 6 Month + 37.49%
  • Over 1 Year + 86.39%
SIP Lightning

Smart Investing Starts Here Start SIP with Themis Medicare for Steady Growth!

Invest Now

Themis Medicare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 50.3
  • PEG Ratio
  • 14.6
  • Market Cap Cr
  • 2,665
  • P/B Ratio
  • 7.1
  • Average True Range
  • 16.75
  • EPS
  • 5.76
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 1.48
  • RSI
  • 60.17
  • MFI
  • 63.01

Themis Medicare Financials

Themis Medicare Technicals

EMA & SMA

Current Price
₹289.55
+ 3.35 (1.17%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹272.97
  • 50 Day
  • ₹267.56
  • 100 Day
  • ₹256.72
  • 200 Day
  • ₹237.73

Resistance and Support

291.8 Pivot Speed
  • R3 322.30
  • R2 314.00
  • R1 300.10
  • S1 277.90
  • S2 269.60
  • S3 255.70

What's your outlook on Themis Medicare?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Themis Medicare Ltd. develops and manufactures pharmaceutical products across segments like anti-infectives, pain management, and critical care. With 3 manufacturing facilities, it serves over 40 countries, offering innovative therapies for a wide range of medical needs.

Themis Medicare has an operating revenue of Rs. 420.33 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 9% is okay, ROE of 11% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 38% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 75 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Themis Medicare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-07-26 Quarterly Results
2024-05-14 Audited Results & Final Dividend
2024-02-10 Quarterly Results
2023-11-04 Quarterly Results
Date Purpose Remarks
2023-10-10 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.

Themis Medicare F&O

Themis Medicare Shareholding Pattern

67.15%
0%
0.1%
0.01%
23.65%
9.09%

About Themis Medicare

  • NSE Symbol
  • THEMISMED
  • BSE Symbol
  • 530199
  • Managing Director & CEO
  • Dr. Sachin D Patel
  • ISIN
  • INE083B01024

Similar Stocks to Themis Medicare

Themis Medicare FAQs

Themis Medicare share price is ₹289 As on 21 November, 2024 | 13:50

The Market Cap of Themis Medicare is ₹2665 Cr As on 21 November, 2024 | 13:50

The P/E ratio of Themis Medicare is 50.3 As on 21 November, 2024 | 13:50

The PB ratio of Themis Medicare is 7.1 As on 21 November, 2024 | 13:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23